Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
We developed a decision analytic model to compare the costs of treatment for an initial 2-year period with finasteride, terazosin, and transurethral resection of the prostate (TURP) in men with at least moderate symptoms of benign prostatic hyperplasia (BPH).
Outcome measures were BPH treatment costs, duration of symptomatic improvement, and lost productivity days (work or other customary activity).
Patterns of health care resource use associated with the treatment of moderate to severe BPH and BPH-related complications were evaluated by a survey of urologists and validated by a urology consensus panel.
BPH safety and efficacy studies in the published literature were used to provide probabilities of treatment success.
Both a national health care resource database (Systemetrics) and Medicare data were used to estimate the costs of specific health care services (such as physician services and laboratory tests).
The probabilities of first-year success (defined as symptomatic improvement) for surgery, finasteride, and terazosin were 88%, 67%, and 74%, respectively.
The most expensive intervention was surgery, followed by finasteride and terazosin, at estimated 24-month costs of $6411, $2860, and $2422 for private insurance and $3874, $2161, and $1820 for Medicare, respectively.
Duration of symptom improvement was comparable for the three treatments.
Mots-clés Pascal : Adénome, Prostate, Finastéride, Inhibiteur enzyme, Térazosine, Résection chirurgicale, Urètre, Endoscopie, Analyse avantage coût, Economie santé, Modèle économique, Etats Unis, Amérique du Nord, Amérique, Evaluation, Traitement, Adulte, Homme, Mâle, Etude comparative, Azastéroïde, Quinazoline dérivé, Appareil urinaire pathologie, Appareil génital mâle pathologie, Prostate pathologie, Tumeur bénigne, Chimiothérapie, Chirurgie
Mots-clés Pascal anglais : Adenoma, Prostate, Enzyme inhibitor, Surgical resection, Urethra, Endoscopy, Cost benefit analysis, Health economy, Economic model, United States, North America, America, Evaluation, Treatment, Adult, Human, Male, Comparative study, Azasteroid, Quinazoline derivatives, Urinary system disease, Male genital diseases, Prostate disease, Benign neoplasm, Chemotherapy, Surgery
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0593405
Code Inist : 002B02I. Création : 01/03/1996.